OMGA (Omega Therapeutics Corp) Earnings per share increase in current year
Year-over-year earnings per share growth demonstrates yield dynamics, where 31.80 reflects the latest metric value. Omega Therapeutics (OMGA) is optimizing the delivery of mRNA products via ultra-cold chains to minimize raw material spoilage. However, revenue shortfalls and testing costs are depleting reserves. Simultaneously, the company is implementing energy saving and emission filtration to comply with environmental standards.
Analytical breakdowns and data insights for company Omega Therapeutics (OMGA)
- share price and expert price forecast:
- business market valuation indicators:
- business book valuation details:
- debt burden and liquidity indicators:
Total Debt to Capital Omega Therapeutics|OMGA - Long-Term Debt to Equity|Current Liabilities to Equity omegatherapeutics.com|OMGA - Company Aggregate Debts|Debts to Book Value Omega Therapeutics Corp|OMGA - Company Long-Term Liabilities|Company Short-Term Debts Omega Therapeutics|Intermediate Liquidity Ratio omegatherapeutics.com
- company profitability and valuation multiples indicators:
OMGA - Net Profit|Company Profit Forecast Omega Therapeutics|OMGA - P/E Multiple|Projected Price to Earnings Omega Therapeutics Corp|OMGA - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Omega Therapeutics Corp|OMGA - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Omega Therapeutics|OMGA - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months omegatherapeutics.com|OMGA - Earnings growth in current year|Net earnings per one share growth forecast for next year Omega Therapeutics
- revenue and sales proceeds data:
Fundamental valuation:OMGA Omega Therapeutics Inc
Fundamental asset selection requires a precise analysis of profit dynamics to avoid overpaying for an asset. This indicator calculates the percentage deviation of net income per share relative to the same period last year, transforming quarterly reports into a continuous data stream. For the pre-revenue Omega Therapeutics (OMGA), rising mRNA research costs directly drive the negative annual EPS growth rate.
Key competitors
TEM: Net earnings per one share growth for the current year|QGEN (Qiagen Group) - Earnings growth in current year|IONS: Earnings per share increase in current year|Earnings growth in current year RGEN|RNA - Earnings per share growth rate in current year|Earnings per share growth in current year CRISPR Therapeutics CRSP|Earnings per share increase in current year WGS|Ultragenyx Pharma - Earnings growth in current year|BEAM - Earnings growth in current year|Sarepta Therapeutics, Inc. (SRPT) - Earnings per share growth in current year|Earnings per share trend in current year TWST (twistbioscience.com)|TXG (10x Genomics) - Earnings growth in current year|Earnings per share growth rate in current year Intellia Therapeutics Inc NTLA|Net earnings per share growth this year STOK (Stoke)|Earnings growth in current year BioLife (BLFS)|Wave Life Sciences - Net earnings per share growth this year|Net earnings per one share growth for the current year MAZE (mazetx.com)|Sionna Therapeutics - Earnings growth in current year|Expected net earnings per share growth this year Prime Medicine Inc PRME|TSHA: Earnings growth in current year|Net earnings per share growth this year uniQure Pharma|Earnings per share growth in current year MeiraGTx Holdings plc|regenxbio.com (RGNX) - Expected net earnings per share growth this year|Earnings per share growth in current year Solid Biosciences (SLDB)|OCGN - Earnings per share growth rate in current year|Earnings per share growth in current year Pacific Biosciences of California PACB|BNTC - Net earnings per share growth this year|Design Therapeutics - Earnings growth in current year|Net earnings per share change in current year rocketpharma.com (RCKT)|FDMT: Earnings growth in current year|Lexeo Therapeutics, Inc. (LXEO) - Earnings growth in current year|KRRO (Korro Bio Inc.) - Earnings growth in current year|Earnings per share growth this year EDIT (Editas Corp)|Earnings per share growth in current year Silence Therapeutics (SLN)|proqr.com - Earnings per share growth this year|Earnings growth in current year CDXS (Codexis)|Earnings growth in current year Sangamo Therapeutics Inc. SGMO|NAUT - Earnings per share growth in current year|Earnings per share growth rate in current year Metagenomi Therapeutics|Precision BioSciences, Inc. (DTIL) - Earnings per share growth in current year|Net earnings per share growth this year Generation Bio|BOLD (Boundless Bio) - Earnings growth in current year|Earnings per share growth rate in current year Exicure Corp XCUR|Earnings growth in current year IMNN|phiopharma.com (PHIO) - Net earnings per share change in current year|Earnings growth in current year MBIO (Mustang Bio)|Earnings growth in current year TransCode Therapeutics Inc. RNAZ|BNGO: Net earnings per share growth this year|Earnings per share increase in current year APDN (Applied DNA Sciences Inc)|BLUE (Bluebird Bio) - Net earnings per share growth this year|IPA: Net earnings per one share growth for the current year|OMIC (Singular Genomics Systems) - Earnings growth in current year|RGLS: Earnings per share increase in current year|Earnings growth in current year SYRS|TBIO - Earnings per share growth rate in current year|Earnings per share growth in current year TRACON TCON|Earnings per share increase in current year UBX
